Why is Eli Lilly down almost $19 for the month? Is it likely to go up sharply in the next few days and before September 30?

Eli Lilly's stock decline can be attributed to several factors:

1. Obesity-Drug Setback: Eli Lilly's stock experienced a significant drop due to concerns over its obesity drug, which is facing increased competition.
2. FDA Delays: The company's shares fell as the FDA unexpectedly pushed back its decision on the Alzheimer's disease treatment donanemab, causing uncertainty.

The likelihood of a sharp increase in Eli Lilly's stock price before September 30 is low, considering the following:

1. Current Sentiment: The sentiment around Eli Lilly is negative, which could make it challenging for the stock to experience a significant recovery in the near term.
2. Lack of Positive Catalysts: There are no imminent positive catalysts, such as a favorable FDA decision, that would typically drive the stock price up.
3. Market Conditions: The broader market conditions, including the performance of the S&P 500, have not been favorable, which could further limit the potential for a sharp increase in Eli Lilly's stock price.

While it is possible that Eli Lilly's stock could recover in the long term, given the company's strong fundamentals and the potential for new drug approvals, the lack of positive catalysts and the current negative sentiment suggest that a sharp increase in the stock price before September 30 is unlikely.